The adverse effects of psychotropic drugs as an endocrine disrupting chemicals on the hypothalamic-pituitary regulation in male

被引:15
作者
Ilgin, Sinem [1 ]
机构
[1] Anadolu Univ, Dept Pharmaceut Toxicol, Fac Pharm, TR-26470 Eskisehir, Turkey
关键词
Psychotropic drugs; hypothalamic; Pituitary; Gonadal axis; adverse reproductive effects; GONADOTROPIN-RELEASING-HORMONE; ANTIPSYCHOTIC-INDUCED HYPERPROLACTINEMIA; GNRH GENE-EXPRESSION; ANTIEPILEPTIC DRUGS; NEURON EXCITABILITY; GONADAL AXIS; NEUROENDOCRINE CONTROL; REPRODUCTIVE HORMONES; COMMON MEDICATIONS; OXIDATIVE STRESS;
D O I
10.1016/j.lfs.2020.117704
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Adverse effects of drugs on male reproductive system can be categorized as pre-testicular, testicular, and post-testicular. Pre-testicular adverse effects disrupt the hypothalamic-pituitary-gonadal (HPG) axis, generally by interfering with endocrine function. It is known that the HPG axis has roles in the maintenance of spermatogenesis and sexual function. The hypothalamus secretes gonadotropin-releasing hormone (GnRH) which enters the hypophyseal portal system to stimulate the anterior pituitary. The anterior pituitary secretes gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) which are vital for spermatogenesis, into the blood. The FSH stimulates the Sertoli cells for the production of regulatory molecules and nutrients needed for the maintenance of spermatogenesis, while the LH stimulates the Leydig cells to produce and secrete testosterone. Many neurotransmitters influence the hypothalamic-pituitary regulation, consequently the HPG axis, and can consequently affect spermatogenesis and sexual function. Psychotropic drugs including antipsychotics, antidepressants, and mood stabilizers that all commonly modulate dopamine, serotonin, and GABA, can affect male spermatogenesis and sexual function by impairment of the hypothalamic-pituitary regulation, act like endocrine-disrupting chemicals. Otherwise, studies have shown the relationship between decreased sperm quality and psychotropic drugs treatment. Therefore, it is important to investigate the adverse reproductive effects of psychotropic drugs which are frequently used during reproductive ages in males and to determine the role of the hypothalamic-pituitary regulation axis on possible pathologies.
引用
收藏
页数:6
相关论文
共 140 条
[21]   Update on male reproductive endocrinology [J].
Clavijo, Raul I. ;
Hsiao, Wayland .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2018, 7 :S367-S372
[22]   Physiology of the Hypothalamic Pituitary Gonadal Axis in the Male [J].
Corradi, Patricia Freitas ;
Corradi, Renato B. ;
Greene, Loren Wissner .
UROLOGIC CLINICS OF NORTH AMERICA, 2016, 43 (02) :151-+
[23]   Pathogenesis of male reproductive toxicity [J].
Creasy, DM .
TOXICOLOGIC PATHOLOGY, 2001, 29 (01) :64-76
[24]  
Daoud AS, 2004, NEUROENDOCRINOL LETT, V25, P178
[25]   Perinatal exposure to fluoxetine via placenta and lactation inhibits the testicular development in male rat offspring [J].
de Oliveira, Waldo Monteiro ;
de Sa, Iana Raphaela ;
de Torres, Sandra Maria ;
de Morais, Rosana Nogueira ;
Andrade, Anderson Martino ;
Lyra Maia, Frederico Celso ;
Tenorio, Bruno Mendes ;
da Silva Junior, Valdemiro Amaro .
SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE, 2013, 59 (05) :244-250
[26]   Drug-induced endocrinopathies and diabetes: a combo-endocrinology overview [J].
Diamanti-Kandarakis, E. ;
Duntas, L. ;
Kanakis, G. A. ;
Kandaraki, E. ;
Karavitaki, N. ;
Kassi, E. ;
Livadas, S. ;
Mastorakos, G. ;
Migdalis, I ;
Miras, A. D. ;
Nader, S. ;
Papalou, O. ;
Poladian, R. ;
Popovic, V ;
Rachon, D. ;
Tigas, S. ;
Tsigos, C. ;
Tsilchorozidou, T. ;
Tzotzas, T. ;
Bargiota, A. ;
Pfeifer, M. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 181 (02) :R73-R105
[27]  
Dimitriadis F., 2017, ENDOCINOLOGY TESTIS, P1, DOI [10.1007/978-3-319-29456-8_33-2, DOI 10.1007/978-30319-29456-8_33-2]
[28]   FDA-approved medications that impair human spermatogenesis [J].
Ding, Jiayi ;
Shang, Xuejun ;
Zhang, Zhanhu ;
Jing, Hua ;
Shao, Jun ;
Fei, Qianqian ;
Rayburn, Elizabeth R. ;
Li, Haibo .
ONCOTARGET, 2017, 8 (06) :10714-10725
[29]   Open-label zonisamide for refractory migraine [J].
Drake, ME ;
Greathouse, NI ;
Renner, JB ;
Armentbright, AD .
CLINICAL NEUROPHARMACOLOGY, 2004, 27 (06) :278-280
[30]  
Drobnis E.Z., 2017, ADV EXPT MED BIOL, P1